Erlotinib performed consistently as previously described10,12, with good potency against EGFR (IC50 = 0.030 μM), weak activity in four of the patient-derived chordoma cell lines, but also with similar non-specific toxicity observed with compound 16 (IC50 = 19 μM). Here, EGFR is linked to chordoma.